Cytoreductive treatment improves the vaccination potential of B7-AML cells. SJL/J mice were injected intravenously with 105 wild-type AML cells (open arrow) and then divided into three different groups. One group (○) received no further treatment. A second group (▪) was treated with Ara-C (•) on days 7, 10, and 14 (protocol I) or 3, 6, and 8 (protocol II), as described in Materials and Methods, but was not vaccinated. A third group of leukemic mice (▴) was treated with Ara-C, and on day 16 (black arrow) was vaccinated with 105 irradiated B7-AML cells. Graph A illustrates the survival of mice treated with protocol I and graph B illustrates the survival of mice treated with protocol II. Each experimental and control group included 8 to 10 mice.
